| scholarly article | Q13442814 |
| P50 | author | Jeffrey I. Weitz | Q29561411 |
| P2093 | author name string | Pascal Druzgala | |
| Daniel Canafax | |||
| Peter Milner | |||
| S. Scott Bowersox | |||
| P2860 | cites work | Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 |
| Primary prevention of ischemic stroke | Q22306369 | ||
| Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition | Q28268992 | ||
| Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range | Q31828961 | ||
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34012421 | ||
| Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy | Q34146486 | ||
| Systematic overview of warfarin and its drug and food interactions | Q34420870 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis | Q35982540 | ||
| Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin | Q35997998 | ||
| Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs | Q37481222 | ||
| Interactions of warfarin with drugs and food | Q38571033 | ||
| Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone | Q40373479 | ||
| Warfarin-induced changes in procoagulant and anticoagulant proteins. | Q40962690 | ||
| The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation | Q43279486 | ||
| The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis | Q43820844 | ||
| Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy | Q43926588 | ||
| The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model | Q44518890 | ||
| Frequency of concurrent use of warfarin with potentially interacting drugs | Q45178248 | ||
| Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522932 | ||
| The potential for interaction between warfarin and coprescribed medication: a retrospective study in primary care | Q46556577 | ||
| Interaction of low molecular weight heparin with ketorolac | Q47331150 | ||
| Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. | Q54640269 | ||
| Potential Drug???Drug Interactions in the Outpatient Setting | Q60622474 | ||
| An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits | Q66905570 | ||
| The stereoselective interaction of warfarin and metronidazole in man | Q67745717 | ||
| The mechanism of the interaction between amiodarone and warfarin in humans | Q68095199 | ||
| Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans | Q69208134 | ||
| The warfarin-sulfinpyrazone interaction: stereochemical considerations | Q69994791 | ||
| Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man | Q71128161 | ||
| Hirudin causes more bleeding than heparin in a rabbit ear bleeding model | Q77295099 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| P304 | page(s) | e383-8 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Thrombosis Research | Q15758741 |
| P1476 | title | Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models | |
| Antithrombotic Activity of the Novel Oral Anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in Animal Models | |||
| P478 | volume | 126 |
| Q35181596 | Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective |
| Q38915899 | Design, Synthesis, and In Vitro Evaluation of Novel 3, 7-Disubstituted Coumarin Derivatives as Potent Anticancer Agents |
| Q47791209 | New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds |
| Q84025388 | [Old and new oral anticoagulants. Pharmacological perspective] |
Search more.